Company intelligence / Profile preview

Oncolinx

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Developing antibody-drug conjugates using patented immune-activating payload Azonafide; partnered with 14 pharma companies and 6 academic labs across 30 cancer indications; no clinical results reported.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugate
Industry: Biotech

Drug pipeline

1 asset

azonafide

Preclinical

Partnerships

National Cancer Institute14 leading pharmaceutical companies6 academic labs

Beyond the preview

Go deeper on Oncolinx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oncolinx.

Explore the full profile